PrimeGen US, Inc. and DT Cloud Star Acquisition Corporation have announced a proposed business combination at an implied equity value of approximately $1.5 billion. The transaction aims to advance PrimeGen US’s stem cell research and development efforts. Further details, including a joint investor presentation and additional documentation, are expected to be made available through filings with the U.S. Securities and Exchange Commission.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DT Cloud Star Acquisition Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9648601-en) on February 04, 2026, and is solely responsible for the information contained therein.